<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063839</url>
  </required_header>
  <id_info>
    <org_study_id>17_120</org_study_id>
    <nct_id>NCT04063839</nct_id>
  </id_info>
  <brief_title>HCV Treatment in a Low-threshold Clinic</brief_title>
  <acronym>Prindsen</acronym>
  <official_title>Management of Hepatitis C Virus Infection Among People Who Inject Drugs in a Low-threshold Setting: Efficacy of Direct-acting Antiviral Treatment and the Risk of Reinfection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at
      a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed
      for to years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at
      a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed
      for to years

      Inclusion Consenting patients older than 18 years attending the low threshold HCV clinic in
      Oslo

      The primary aims are to assess the efficacy (SVR rate) of DAA treatment among PWID treated in
      a low-threshold primary care setting (Work Package 1) and to estimate the incidence HCV
      reinfection f

      The secondary aims are to:

        -  Evaluate adherence to DAA treatment (Work Package 1)

        -  Identify factors associated with SVR and adherence (Work Package 1)

        -  Characterize reinfection using next generation sequencing (Work Package 2)

        -  Identify factors associated with reinfection (Work Package 2)

        -  Evaluate changes in recent injecting risk behaviours longitudinally (Work Package 2)

        -  Identify factors associated with changes in risk behaviours (Work Package 2)

      The hypothesis is that high SVR rates and good treatment adherence will be achieved in PWID
      treated for HCV infection in a low-threshold primary health care setting. Further,it is
      anticipated that the incidence of reinfection will be 5-10/100 PY and associated with younger
      age, low education level and ongoing injecting risk behaviours.

      The study will include 300 patients and are close to achieving that aim the summer of 2019
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>12 weeks</time_frame>
    <description>HCV RNA undetectable 12 weeks post treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reinfection</measure>
    <time_frame>2 years</time_frame>
    <description>HCV RNA detectable after SVR 12 in a patient who injected drugs post SVR 12</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Substance Use Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir / Grazoprevir Oral Tablet</intervention_name>
    <description>HCV treatment according to Norwegian guidelines</description>
    <other_name>sofosbuvir</other_name>
    <other_name>ledipasvir</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma collected at baseline and stored frozen -70 C
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ever injected drugs (100%) OAT (70%) Recent injecting drug use (70%)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA positive Attending the low-threshold HCV clinic in Oslo

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Dalgard, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olav Dalgard, MD PhD</last_name>
    <phone>92616800</phone>
    <phone_ext>47</phone_ext>
    <email>odalgard@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kjersti Ulstein, MD</last_name>
    <phone>41226162</phone>
    <phone_ext>47</phone_ext>
    <email>kjersti.ulstein@vel.oslo.kommune</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AkershusUH</name>
      <address>
        <city>LÃ¸renskog</city>
        <state>Select A State Or Province</state>
        <zip>0278</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav Dalgard, MD PhD</last_name>
      <phone>92616800</phone>
      <email>odalgard@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Kjersti Ulstein, MD PhD</last_name>
      <phone>41226162</phone>
      <phone_ext>0047</phone_ext>
      <email>kjersti.ulstein@vel.oslo.kommune.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Olav Dalgard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>MK-5172</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>depends on patient privacy decission</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

